Advertisement

Topics

Steve Powell named SynteractHCR CEO

13:40 EDT 17 Jul 2017 | CentreWatch

SynteractHCR announced that Steve Powell has been appointed chief executive officer. Powell succeeds Wendel Barr, who departs SynteractHCR after six years as CEO. A portfolio company of Amulet Capital Partners, LP, SynteractHCR is a leading, international CRO focused on phase I-IV clinical trials for innovative biopharma clients in the U.S., Europe and Asia. Powell has more […]

The post Steve Powell named SynteractHCR CEO appeared first on CenterWatch News Online.

Original Article: Steve Powell named SynteractHCR CEO

NEXT ARTICLE

More From BioPortfolio on "Steve Powell named SynteractHCR CEO"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...